23andMe and GLP‑1 predictions
- Public posts highlight a 23andMe‑linked analysis claiming genetic profiles can predict GLP‑1 treatment benefit ( ). - The shared analysis reportedly used tens of thousands of patients and flags variants tied to both efficacy and gastrointestinal side effects ( ). - Consumer genetic data entering clinical debates raises questions about validity, privacy, and real‑world usefulness ( ).
A new 23andMe study says common DNA variants can help predict who loses more weight on GLP-1 drugs and who is more likely to get nausea or vomiting. (nature.com) Glucagon-like peptide 1 drugs, including semaglutide and tirzepatide, mimic gut hormones that curb appetite, slow stomach emptying, and improve blood sugar control. They have become widely used for obesity treatment, but response varies sharply from person to person. (nature.com) The paper, published in *Nature* on April 8, 2026, analyzed self-reported outcomes from 27,885 people who had used GLP-1 receptor agonists. Researchers found a missense variant in the GLP1R gene linked to greater weight loss, with about 0.76 kilograms of additional loss per copy of the effect allele. (nature.com) The same study linked variation in GLP1R and GIPR to nausea or vomiting, and said the GIPR signal appeared only in tirzepatide users, not semaglutide users. 23andMe said its broader response model combined genetic, demographic, and clinical factors to sort people by efficacy and side-effect risk. (nature.com; mediacenter.23andme.com) 23andMe is not presenting the work only as a journal paper. The company is also selling a GLP-1 report and interactive tool through its Total Health subscription, which uses exome sequencing, blood biomarkers, and clinician oversight. (mediacenter.23andme.com; 23andme.com) That commercial push lands after 23andMe’s March 23, 2025 Chapter 11 filing, which put its genetic-data business under new scrutiny. The Federal Trade Commission said in March 2025 that consumers should be able to trust companies to keep promises about handling sensitive information during any sale or transfer. (restructuring.ra.kroll.com; ftc.gov) Privacy questions were already hanging over the company after its 2023 breach. 23andMe said hackers accessed about 14,000 accounts and exposed profile data tied to roughly 6.9 million users, then required password resets and two-step verification for all customers. (blog.23andme.com; hipaajournal.com) The science itself also comes with limits. The *Nature* study used self-reported weight loss and side effects, and the paper says the findings lay a foundation for precision medicine rather than a finished clinical test. (nature.com) Researchers have been looking for these signals for years because GLP-1 drugs do not work the same way in every body. A 2022 *Lancet Diabetes & Endocrinology* genome-wide analysis also examined pharmacogenomics of GLP-1 receptor agonists, showing the field predates this 23andMe paper even as the new dataset is much larger and more consumer-facing. (thelancet.com; nature.com) For now, the clearest shift is that consumer DNA data is moving closer to treatment decisions for blockbuster obesity drugs. The paper shows one route for that move; the unanswered part is whether doctors, regulators, and patients will treat a consumer-genetics score as ready for routine care. (nature.com; ftc.gov)
